1 | difference | 66,404 |
2 | tfsq | 5 |
3 | deltaqtcf | 4 |
4 | pcfb | 4 |
5 | prophylaxis/placebo | 4 |
6 | defferences | 3 |
7 | difference=-0.17 | 3 |
8 | g-index | 3 |
9 | time-to-ovulation | 3 |
10 | 2,4-dioxygenase | 2 |
11 | broad-nosed | 2 |
12 | change/reduction | 2 |
13 | cipulseco | 2 |
14 | emoticon | 2 |
15 | heterotropia | 2 |
16 | p/s-ratio | 2 |
17 | ph/fh | 2 |
18 | thromboembolism-prevention | 2 |
19 | δ-f | 2 |
20 | ∆d6s | 2 |
21 | -0.01º | 1 |
22 | -0.6±1.6 | 1 |
23 | -123·1 | 1 |
24 | -lnl | 1 |
25 | 0.05ml | 1 |
26 | 0.6-point | 1 |
27 | 094-2 | 1 |
28 | 1.110-1.304 | 1 |
29 | 1.195±0.32×10 | 1 |
30 | 1.228-1.579 | 1 |
31 | 1.780±0.32×10 | 1 |
32 | 101,747 | 1 |
33 | 191± | 1 |
34 | 24,153 | 1 |
35 | 24h-systolic | 1 |
36 | 3,923 | 1 |
37 | 3.3-1.5 | 1 |
38 | 42.65 | 1 |
39 | 5-methylthio-1 | 1 |
40 | 5.19s | 1 |
41 | 68,654 | 1 |
42 | 7.4-point | 1 |
43 | 74.14 | 1 |
44 | 937/qaly | 1 |
45 | age=19.28 | 1 |
46 | age=45.9 | 1 |
47 | age=53+/-13 | 1 |
48 | bradyspnea | 1 |
49 | cardioinhibition | 1 |
50 | cariation | 1 |
51 | change/deterioration | 1 |
52 | conduit/material | 1 |
53 | conversion/reoperation | 1 |
54 | cough/coryza | 1 |
55 | cyr | 1 |
56 | diastolic≥30mmhg | 1 |
57 | difference-11.9 | 1 |
58 | difference.rt-3d-tee | 1 |
59 | difference=-1.76 | 1 |
60 | difference=0.29 | 1 |
61 | difference=0.77 | 1 |
62 | dna-ase | 1 |
63 | dpphic50 | 1 |
64 | ecc*s | 1 |
65 | effect.antihistamine-analgesic | 1 |
66 | effective-dose | 1 |
67 | ellison | 1 |
68 | evaluations.differences | 1 |
69 | ffa-ogtt | 1 |
70 | fold-rises | 1 |
71 | foldrise | 1 |
72 | galgen-tang | 1 |
73 | graft-number | 1 |
74 | gusher | 1 |
75 | handguns | 1 |
76 | hss-score | 1 |
77 | improvement/resolved | 1 |
78 | isrctn79628180 | 1 |
79 | kolmogorov-arnold-moser | 1 |
80 | lvef-reduction | 1 |
81 | m1:02 | 1 |
82 | nct00599885 | 1 |
83 | onset-to-randomization | 1 |
84 | orthokeratosis | 1 |
85 | others/caregivers | 1 |
86 | pain,1 | 1 |
87 | petsevo | 1 |
88 | post-β | 1 |
89 | redo-operation | 1 |
90 | reiley | 1 |
91 | signal-signal | 1 |
92 | tc/hdl-ratio | 1 |
93 | test/referenceratios | 1 |
94 | time-to-answer | 1 |
95 | transfusion/placebo | 1 |
96 | treatment-by-tsh | 1 |
97 | trust/mistrust | 1 |
98 | tsn-incubation | 1 |
99 | ua-ot | 1 |
100 | δ-change | 1 |
101 | δodss | 1 |
102 | δpefsal-δpefmon | 1 |
1 | -0.01º | 1 |
2 | -0.6±1.6 | 1 |
3 | -123·1 | 1 |
4 | -lnl | 1 |
5 | 0.05ml | 1 |
6 | 0.6-point | 1 |
7 | 094-2 | 1 |
8 | 1.110-1.304 | 1 |
9 | 1.195±0.32×10 | 1 |
10 | 1.228-1.579 | 1 |
11 | 1.780±0.32×10 | 1 |
12 | 101,747 | 1 |
13 | 191± | 1 |
14 | 2,4-dioxygenase | 2 |
15 | 24,153 | 1 |
16 | 24h-systolic | 1 |
17 | 3,923 | 1 |
18 | 3.3-1.5 | 1 |
19 | 42.65 | 1 |
20 | 5-methylthio-1 | 1 |
21 | 5.19s | 1 |
22 | 68,654 | 1 |
23 | 7.4-point | 1 |
24 | 74.14 | 1 |
25 | 937/qaly | 1 |
26 | age=19.28 | 1 |
27 | age=45.9 | 1 |
28 | age=53+/-13 | 1 |
29 | bradyspnea | 1 |
30 | broad-nosed | 2 |
31 | cardioinhibition | 1 |
32 | cariation | 1 |
33 | change/deterioration | 1 |
34 | change/reduction | 2 |
35 | cipulseco | 2 |
36 | conduit/material | 1 |
37 | conversion/reoperation | 1 |
38 | cough/coryza | 1 |
39 | cyr | 1 |
40 | defferences | 3 |
41 | deltaqtcf | 4 |
42 | diastolic≥30mmhg | 1 |
43 | difference | 66,404 |
44 | difference-11.9 | 1 |
45 | difference.rt-3d-tee | 1 |
46 | difference=-0.17 | 3 |
47 | difference=-1.76 | 1 |
48 | difference=0.29 | 1 |
49 | difference=0.77 | 1 |
50 | dna-ase | 1 |
51 | dpphic50 | 1 |
52 | ecc*s | 1 |
53 | effect.antihistamine-analgesic | 1 |
54 | effective-dose | 1 |
55 | ellison | 1 |
56 | emoticon | 2 |
57 | evaluations.differences | 1 |
58 | ffa-ogtt | 1 |
59 | fold-rises | 1 |
60 | foldrise | 1 |
61 | g-index | 3 |
62 | galgen-tang | 1 |
63 | graft-number | 1 |
64 | gusher | 1 |
65 | handguns | 1 |
66 | heterotropia | 2 |
67 | hss-score | 1 |
68 | improvement/resolved | 1 |
69 | isrctn79628180 | 1 |
70 | kolmogorov-arnold-moser | 1 |
71 | lvef-reduction | 1 |
72 | m1:02 | 1 |
73 | nct00599885 | 1 |
74 | onset-to-randomization | 1 |
75 | orthokeratosis | 1 |
76 | others/caregivers | 1 |
77 | p/s-ratio | 2 |
78 | pain,1 | 1 |
79 | pcfb | 4 |
80 | petsevo | 1 |
81 | ph/fh | 2 |
82 | post-β | 1 |
83 | prophylaxis/placebo | 4 |
84 | redo-operation | 1 |
85 | reiley | 1 |
86 | signal-signal | 1 |
87 | tc/hdl-ratio | 1 |
88 | test/referenceratios | 1 |
89 | tfsq | 5 |
90 | thromboembolism-prevention | 2 |
91 | time-to-answer | 1 |
92 | time-to-ovulation | 3 |
93 | transfusion/placebo | 1 |
94 | treatment-by-tsh | 1 |
95 | trust/mistrust | 1 |
96 | tsn-incubation | 1 |
97 | ua-ot | 1 |
98 | δ-change | 1 |
99 | δ-f | 2 |
100 | δodss | 1 |
101 | δpefsal-δpefmon | 1 |
102 | ∆d6s | 2 |
1 | 1.780±0.32×10 | 1 |
2 | 1.195±0.32×10 | 1 |
3 | dpphic50 | 1 |
4 | isrctn79628180 | 1 |
5 | pain,1 | 1 |
6 | 5-methylthio-1 | 1 |
7 | -123·1 | 1 |
8 | 094-2 | 1 |
9 | m1:02 | 1 |
10 | age=53+/-13 | 1 |
11 | 3,923 | 1 |
12 | 24,153 | 1 |
13 | 1.110-1.304 | 1 |
14 | 74.14 | 1 |
15 | 68,654 | 1 |
16 | 3.3-1.5 | 1 |
17 | 42.65 | 1 |
18 | nct00599885 | 1 |
19 | -0.6±1.6 | 1 |
20 | difference=-1.76 | 1 |
21 | difference=-0.17 | 3 |
22 | 101,747 | 1 |
23 | difference=0.77 | 1 |
24 | age=19.28 | 1 |
25 | difference-11.9 | 1 |
26 | age=45.9 | 1 |
27 | difference=0.29 | 1 |
28 | 1.228-1.579 | 1 |
29 | bradyspnea | 1 |
30 | heterotropia | 2 |
31 | cough/coryza | 1 |
32 | pcfb | 4 |
33 | 24h-systolic | 1 |
34 | effect.antihistamine-analgesic | 1 |
35 | broad-nosed | 2 |
36 | improvement/resolved | 1 |
37 | difference | 66,404 |
38 | difference.rt-3d-tee | 1 |
39 | δ-change | 1 |
40 | hss-score | 1 |
41 | dna-ase | 1 |
42 | 2,4-dioxygenase | 2 |
43 | foldrise | 1 |
44 | effective-dose | 1 |
45 | δ-f | 2 |
46 | deltaqtcf | 4 |
47 | diastolic≥30mmhg | 1 |
48 | galgen-tang | 1 |
49 | ph/fh | 2 |
50 | treatment-by-tsh | 1 |
51 | conduit/material | 1 |
52 | signal-signal | 1 |
53 | 0.05ml | 1 |
54 | -lnl | 1 |
55 | emoticon | 2 |
56 | tsn-incubation | 1 |
57 | cariation | 1 |
58 | time-to-ovulation | 3 |
59 | redo-operation | 1 |
60 | conversion/reoperation | 1 |
61 | change/deterioration | 1 |
62 | onset-to-randomization | 1 |
63 | lvef-reduction | 1 |
64 | change/reduction | 2 |
65 | cardioinhibition | 1 |
66 | thromboembolism-prevention | 2 |
67 | δpefsal-δpefmon | 1 |
68 | ellison | 1 |
69 | transfusion/placebo | 1 |
70 | prophylaxis/placebo | 4 |
71 | cipulseco | 2 |
72 | tc/hdl-ratio | 1 |
73 | p/s-ratio | 2 |
74 | petsevo | 1 |
75 | tfsq | 5 |
76 | graft-number | 1 |
77 | gusher | 1 |
78 | kolmogorov-arnold-moser | 1 |
79 | time-to-answer | 1 |
80 | cyr | 1 |
81 | ecc*s | 1 |
82 | ∆d6s | 2 |
83 | 5.19s | 1 |
84 | defferences | 3 |
85 | evaluations.differences | 1 |
86 | fold-rises | 1 |
87 | orthokeratosis | 1 |
88 | handguns | 1 |
89 | test/referenceratios | 1 |
90 | others/caregivers | 1 |
91 | δodss | 1 |
92 | 7.4-point | 1 |
93 | 0.6-point | 1 |
94 | ua-ot | 1 |
95 | trust/mistrust | 1 |
96 | ffa-ogtt | 1 |
97 | g-index | 3 |
98 | reiley | 1 |
99 | 937/qaly | 1 |
100 | 191± | 1 |
101 | post-β | 1 |
102 | -0.01º | 1 |